Talon Therapeutics Inc. will seek accelerated approval from the Food and Drug Administration for its experimental treatment of a type of leukemia.
San Mateo-based Talon said Monday that it filed a new drug application for Marqibo, a capsule form of the FDA-approved anticancer drug vincristine, against adult Philadelphia chromosome negative acute lymphoblastic leukemia. Talon (OTC BB: TLON) said its drug could last longer in the blood and accumulate at the tumor site, increasing the amount of vincristine delivered to the tumor.
No comments:
Post a Comment